Arestin is a drug owned by Orapharma Inc. It is protected by 2 US drug patents filed from 2013 to 2015 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 29, 2022. Details of Arestin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6682348 | Dispensing apparatus and cartridge |
Mar, 2022
(2 years ago) |
Expired
|
| US7699609 | Dispensing apparatus and cartridge with deformable tip |
Mar, 2022
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Arestin's patents.
Latest Legal Activities on Arestin's Patents
Given below is the list of recent legal activities going on the following patents of Arestin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Sep, 2021 | US7699609 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Sep, 2017 | US7699609 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Apr, 2010 | US7699609 |
| Recordation of Patent Grant Mailed Critical | 20 Apr, 2010 | US7699609 |
| Email Notification Critical | 01 Apr, 2010 | US7699609 |
| Issue Notification Mailed Critical | 31 Mar, 2010 | US7699609 |
| Dispatch to FDC | 10 Mar, 2010 | US7699609 |
| Application Is Considered Ready for Issue Critical | 09 Mar, 2010 | US7699609 |
| Issue Fee Payment Received Critical | 02 Mar, 2010 | US7699609 |
| Issue Fee Payment Verified Critical | 02 Mar, 2010 | US7699609 |
US patents provide insights into the exclusivity only within the United States, but Arestin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Arestin's family patents as well as insights into ongoing legal events on those patents.
Arestin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Arestin's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 29, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Arestin Generic API suppliers:
Minocycline Hydrochloride is the generic name for the brand Arestin. 26 different companies have already filed for the generic of Arestin, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Arestin's generic
Alternative Brands for Arestin
There are several other brand drugs using the same active ingredient (Minocycline Hydrochloride) as Arestin. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Minocycline Hydrochloride, Arestin's active ingredient. Check the complete list of approved generic manufacturers for Arestin
About Arestin
Arestin is a drug owned by Orapharma Inc. Arestin uses Minocycline Hydrochloride as an active ingredient. Arestin was launched by Orapharma in 2001.
Approval Date:
Arestin was approved by FDA for market use on 16 February, 2001.
Active Ingredient:
Arestin uses Minocycline Hydrochloride as the active ingredient. Check out other Drugs and Companies using Minocycline Hydrochloride ingredient
Dosage:
Arestin is available in powder, extended release form for dental use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1MG BASE | POWDER, EXTENDED RELEASE | Prescription | DENTAL |